Comparative Pharmacology
Head-to-head clinical analysis: ESOMEPRAZOLE SODIUM versus PRILOSEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESOMEPRAZOLE SODIUM versus PRILOSEC.
ESOMEPRAZOLE SODIUM vs PRILOSEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that irreversibly inhibits the H+/K+-ATPase enzyme system (proton pump) in gastric parietal cells, suppressing gastric acid secretion.
Omeprazole is a proton pump inhibitor that irreversibly inhibits the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells, thereby blocking the final step of gastric acid secretion.
20-40 mg IV once daily for up to 10 days; oral: 20-40 mg once daily for 4-8 weeks for erosive esophagitis, 20 mg once daily for gastroesophageal reflux disease.
20 mg orally once daily before a meal for 4-8 weeks for GERD; for duodenal ulcer, 20 mg once daily for 4 weeks; for Zollinger-Ellison syndrome, initial dose 60 mg orally once daily, titrate up to 120 mg three times daily as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 1–1.5 hours in healthy individuals; clinical context: longer half-life (~2–3 hours) in slow CYP2C19 metabolizers, but acid suppression lasts longer due to irreversible binding to H+/K+-ATPase.
Terminal elimination half-life: 0.5–1 hour in healthy subjects (elimination phase); clinical context: acid suppression persists >24 hours due to irreversible binding to parietal cell H+/K+-ATPase.
Primarily hepatic metabolism (~80%) via CYP2C19 and CYP3A4; renal excretion of inactive metabolites accounts for ~80% of an oral dose, with ~20% excreted in feces via bile.
Renal: ~77% as metabolites; fecal: ~20% as metabolites (biliary/fecal). Unchanged drug negligible.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor